Recently, pharmaceutical inhibitors targeting MDM2 and MDM4 have been explored to reactive the p53/Rb tumor suppressor function; and the preliminary response data from the clinical trial in acute myeloid leukemia patients have been gaining increasing interest (Burgess et al., 2016; Vu et al., 2020). Here, RB1 is linked to acute myeloid leukemia.